This test is most useful if any of these apply to you.
You can have a vitamin B12 level that lands squarely in the normal range and still be functionally deficient. The classic blood test counts how much B12 is floating in your bloodstream, not how much your cells are actually using. This test measures a downstream byproduct that piles up when the B12 machinery inside your cells starts to stall, often years before classic symptoms like nerve tingling, fatigue, or memory problems appear.
MMA (methylmalonic acid) in urine is a functional read on vitamin B12 status. It catches the deficiency that hides behind a normal B12 number, and unlike the blood version of the test, it holds up better when your kidney function is not perfect. For anyone over 60, anyone on a plant-based diet, anyone on long-term acid-suppressing drugs or metformin, or anyone with unexplained neurological symptoms, this is the test that can answer the question your routine labs cannot.
MMA is a small organic acid your body makes inside the energy-producing compartments of your cells (the mitochondria) when it breaks down certain amino acids from protein and certain fats. Normally, vitamin B12 helps convert MMA into a different molecule that feeds your energy cycle. When B12 is in short supply or cannot do its job, MMA backs up, spills into your blood, and gets excreted in urine.
The urinary test typically reports MMA relative to creatinine (a stable waste product), giving a uMMA/creatinine ratio. This corrects for how concentrated your urine is. The blood and urine versions of the test track the same underlying biology, but they behave differently when your kidneys are not at full capacity. Blood MMA rises as kidney filtration drops, even when B12 is fine. The urinary ratio is less affected by mild to moderate kidney impairment, which is part of why it is useful as a second look when blood results are ambiguous.
A standard serum B12 test measures how much vitamin is in circulation. It does not tell you whether your cells can actually grab it and put it to work. In one study of hospitalized adults, urinary MMA/creatinine identified B12 deficiency with about 88% specificity and 55% sensitivity at a defined cutpoint. Older work using a different cutpoint reported even higher diagnostic accuracy, catching essentially every confirmed deficiency.
What makes this clinically useful is the gap it fills. People with neurological symptoms and a B12 level in the low-normal range often have elevated MMA, and they often respond to B12 treatment. Relying on serum B12 alone, especially in older adults or people on medications that block B12 absorption, leads to missed diagnoses. MMA, along with homocysteine, is the functional check that catches what serum B12 misses.
Beyond B12 deficiency, urinary MMA is the diagnostic foundation for a group of rare inherited disorders called methylmalonic acidemias. In these conditions, mutations in genes like MMUT or related cobalamin-pathway genes block the same conversion step, and urinary MMA can be massively elevated. The level of urinary MMA correlates with disease severity and predicts complications. In one cohort of patients with inherited MMA disorders, higher urinary MMA excretion was associated with later development of chronic kidney failure.
These disorders are usually picked up in infancy through newborn screening, but late-onset adult forms exist and can present with subtle neurological symptoms, anemia, or kidney problems that get missed for years. If your urinary MMA is dramatically elevated and B12 deficiency has been ruled out, this is one of the conditions that needs to be considered.
Beyond B12 status, MMA reflects broader health signals. Most of the evidence linking elevated MMA to disease comes from studies measuring serum or plasma MMA, not urinary MMA specifically. The two are correlated but not identical measurements. With that caveat, here is what the serum-based research shows.
In a study of over 23,000 adults from a U.S. health survey, people with higher serum MMA had a substantially elevated risk of dying from any cause and from cardiovascular disease during follow-up. In adults with existing coronary heart disease, higher serum MMA independently predicted cardiovascular mortality. In patients with chronic kidney disease, higher circulating MMA was strongly associated with all-cause and cardiovascular mortality even when serum vitamin B12 was normal. Whether urinary MMA tracks the same risks at the same magnitude has not been directly tested at this scale.
Serum MMA rises when kidney filtration slows, and in older adults with chronic kidney disease, higher serum MMA was independently linked to cognitive dysfunction. In a pilot trial in older adults given high-dose oral B12, the people whose uMMA/creatinine ratio fell the most also showed the biggest improvements in balance and cognitive testing. This suggests that lowering MMA tracks meaningful functional improvements, not just lab numbers.
Higher serum MMA has been linked to faster biological aging, low muscle mass, and depression in large population studies. Whether this reflects pure B12 deficiency, broader mitochondrial dysfunction, or both is still being worked out. What is clear is that MMA is not just a B12 marker. It is a window into how well your cellular energy machinery is running.
Urinary MMA varies with diet, hydration, kidney function, and time of day, so a single value should be the start of a story, not the end. The most useful approach is a baseline reading followed by a retest after any intervention. If you start B12 supplementation or switch routes (oral to injectable), retest in 8 to 12 weeks to confirm the response. If you are tracking general nutritional and metabolic health, retest at least annually. People with confirmed deficiency under treatment, or with inherited MMA disorders, need more frequent monitoring under specialist care.
The Hill randomized trial illustrated why timing and dose matter. In elderly people with moderately poor B12 status, 500 µg per day of oral B12 for 8 weeks failed to fully normalize urinary MMA. This means that if you start a supplement and retest too soon, or use too low a dose, your follow-up number may still look elevated even though you are heading in the right direction. Track the trend, not the snapshot.
A mildly elevated urinary MMA in someone with no obvious risk factor usually points to early functional B12 deficiency. The next steps are to check serum vitamin B12 (or holotranscobalamin, the active form), homocysteine (another functional B12 marker), folate, and a CBC (complete blood count, which can show macrocytic anemia from B12 deficiency). If you take a proton pump inhibitor, metformin, or had bariatric surgery, those alone can drive B12 deficiency and warrant investigation.
If urinary MMA is markedly elevated and B12 deficiency has been excluded, the workup shifts. Check kidney function with cystatin C and eGFR (estimated glomerular filtration rate), because impaired clearance raises MMA. Plasma MMA, plasma homocysteine, and an organic acid panel can clarify whether you are dealing with an inherited disorder, acquired deficiency, or kidney-related accumulation. An adult-onset inherited MMA disorder is rare but real, and confirmation involves a metabolic specialist, plasma acylcarnitines, and genetic testing for MMUT or related genes.
Evidence-backed interventions that affect your Methylmalonic Acid level
Methylmalonic Acid is best interpreted alongside these tests.
Methylmalonic Acid is included in these pre-built panels.